Prevention Of Drug Toxicities With Dichloroacetic Acid - The Implications For Cancer Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$539,839.00
Summary
Many valuable cancer drugs have limited clinical use because of their toxic side effects. Our experiments with a new anti cancer drug called dichloroacetic acid (DCA) will determine if it can reduce the toxic effects of Cisplatin on the kidney and the effects of Doxorubicin on the heart.
Improving Treatment Of Non-small Cell Lung Cancer: Suppressing Cell Division Cycle Associated Protein 3 (CDCA3)
Funder
National Health and Medical Research Council
Funding Amount
$194,446.00
Summary
Lung cancer is the leading cause of cancer-related mortality worldwide. This project will establish the worth of suppressing the molecule ‘cell division cycle associated protein 3’ (CDCA3) in lung cancer. To do so, we will adjust the levels of CDCA3 in animal lung cancer models and treat the tumours with chemotherapy and the novel drug CX-4945. We expect that reduced levels of CDCA3 combined with CX-4945 and/or chemotherapy in NSCLC patients will benefit patient outcome.